Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trialSara A. Hurvitz, Javier Cortés, José Manuel Pérez-García et al.|The Lancet|2022Cited by 664
Phase 1/2A Study of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) in Patients with Brain Metastases (Bm) from Solid Tumors or Recurrent High Grade Gliomas (Hgg)Dieta Brandsma, Philippe Aftimos, Bojana Milojkovic Kerklaan et al.|Annals of Oncology|2014Cited by 33
NT-23 * PHASE 1/2A STUDY OF GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN (2B3-101) IN BREAST CANCER PATIENTS WITH BRAIN METASTASES (BCBM) OR RECURRENT HIGH GRADE GLIOMAS (HGG)Bojana Milojkovic Kerklaan, Dieta Brandsma, Agnes Jager et al.|Neuro-Oncology|2014Cited by 14
Abstract GS2-02: GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03Sara A. Hurvitz, Javier Cortés, Roberto Hegg et al.|Cancer Research|2023Cited by 12
P08.03 * 2B3-101, GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS AND BREAST CANCER BRAIN METASTASESDieta Brandsma, Philippe Aftimos, Véronique Dièras et al.|Neuro-Oncology|2014Cited by 11